Halozyme Therapeutics Inc [NASDAQ: HALO] loss -24.56% or -16.35 points to close at $50.23 with a heavy trading volume of 13995594 shares.
The daily chart for HALO points out that the company has recorded -15.79% loss over the past six months.
If we look at the average trading volume of 1.74M shares, HALO reached to a volume of 13995594 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Halozyme Therapeutics Inc [HALO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HALO shares is $68.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HALO stock is a recommendation set at 2.11. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Halozyme Therapeutics Inc shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on May 13, 2025. While these analysts kept the previous recommendation, Wells Fargo raised their target price from $58 to $62. The new note on the price target was released on October 07, 2024, representing the official price target for Halozyme Therapeutics Inc stock. Previously, the target price had yet another raise from $52 to $57, while JP Morgan kept a Neutral rating on HALO stock. On June 07, 2024, analysts increased their price target for HALO shares from 48 to 51.
The Average True Range (ATR) for Halozyme Therapeutics Inc is set at 4.10, with the Price to Sales ratio for HALO stock in the period of the last 12 months amounting to 5.71. The Price to Book ratio for the last quarter was 12.83, with the Price to Cash per share for the same quarter was set at 6.07. Price to Free Cash Flow for HALO in the course of the last twelve months was 12.48 with Quick ratio for the last quarter at 7.30.
Trading performance analysis for HALO stock
Halozyme Therapeutics Inc [HALO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.41. With this latest performance, HALO shares dropped by -16.59% in over the last four-week period, additionally sinking by -15.79% over the last 6 months – not to mention a rise of 14.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HALO stock in for the last two-week period is set at 34.42, with the RSI for the last a single of trading hit 30.01, and the three-weeks RSI is set at 37.40 for Halozyme Therapeutics Inc [HALO]. The present Moving Average for the last 50 days of trading for this stock 61.41, while it was recorded at 64.11 for the last single week of trading, and 56.47 for the last 200 days.
Halozyme Therapeutics Inc [HALO]: A deeper dive into fundamental analysis
Halozyme Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.30 and a Current Ratio set at 8.39.
Halozyme Therapeutics Inc [HALO]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HALO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Halozyme Therapeutics Inc go to 28.69%.
An analysis of Institutional ownership at Halozyme Therapeutics Inc [HALO]
There are presently around $103.26%, or 104.48%% of HALO stock, in the hands of institutional investors. The top three institutional holders of HALO stocks are: BLACKROCK INC. with ownership of 17.62 million shares, which is approximately 13.8613%. VANGUARD GROUP INC, holding 12.88 million shares of the stock with an approximate value of $$674.47 million in HALO stocks shares; and VANGUARD GROUP INC, currently with $$304.43 million in HALO stock with ownership which is approximately 4.5739%.
